La cadena de opciones muestra datos clave de las opciones de acciones de Cardiol Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cardiol Therapeutics..

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Cadena de Opciones

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Press Releases

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

CRDL

TSX:CRDL

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cybin

Hyperion DeFi

ImageneBio

Intercure

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

NRX Pharmaceuticals

Nasus Pharma

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Cardiol Therapeutics

Cardiol Therapeutics (CRDL) Opciones

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL